Why the study?
Pathological cardiac hypertrophy progresses to heart failure, and understanding regulated cell death pathways is needed to provide new ideas for developing targeted therapeutic approaches.
Understanding regulated cell death pathways offers potential new cellular-level therapeutic targets to prevent or reverse pathological cardiac hypertrophy.
Answers are grounded in this paper and cite their sources.
RCD pathways may drive hypertrophy-to-HF progression; leaves open targeted therapies pending prospective validation.
Cardiac hypertrophy is characterized by an increased volume of individual cardiomyocytes rather than an increase in their number. Myocardial hypertrophy due to pathological stimuli encountered by the heart, which reduces pressure on the ventricular walls to maintain cardiac function, is known as pathological hypertrophy. This eventually progresses to heart failure. Certain varieties of regulated cell death (RCD) pathways, including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagy, are crucial in the development of pathological cardiac hypertrophy. This review summarizes the molecular mechanisms and signaling pathways underlying these RCD pathways, focusing on their mechanism of action findings for pathological cardiac hypertrophy. It intends to provide new ideas for developing therapeutic approaches targeted at the cellular level to prevent or reverse pathological cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: